Thanks to the pioneering work of Jérôme Galon, HalioDx provides a unique range of immune scoring solutions based on the analysis and the understanding of the immune contexture of tumor, a key determinant of patients’ outcomes and response to cancer treatment.
Conducted in a Research or GCP/GCLP environment, the HalioDx Clinical Research tests are now part of cancer Immunogram, a multi-parameter approach that offers a personalized and dynamic “fingerprint” of tumor-immune system interaction.
HalioDx has an experienced team of more than 140 employees, a CLIA-certified laboratory and compliant facilities to develop, manufacture, register and market in vitro diagnostic (IVD) products. HalioDx executes biomarker studies and companion diagnostic assay development in conformity with regulations and in partnership with biopharmaceutical companies.